Geyer CE Jr, Garber JE, Gelber RD, Yothers G, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. Ann Oncol 2022 Oct 10. pii: S0923-7534(22)04165.
PMID: 36228963